Do analysts recommend NLTX or ALVO?

Alvotech has a consensus price target of $7.50, indicating a potential upside of 39.41%. Given Alvotech's stronger consensus rating and higher possible upside, analysts plainly believe Alvotech is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alvotech 2 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer NLTX or REPL?

Replimune Group has a consensus price target of $12.00, indicating a potential downside of 21.52%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Replimune Group 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable valuation and earnings, NLTX or REPL?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is NLTX or REPL more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Replimune Group N/A -159.32% -90.84%

Do analysts recommend CGEM or NLTX?

Cullinan Therapeutics currently has a consensus price target of $32.86, indicating a potential upside of 48.27%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cullinan Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cullinan Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, CGEM or NLTX?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cullinan Therapeutics N/A N/A -$219.88M -$3.10 N/A Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A

Is CGEM or NLTX more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Cullinan Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cullinan Therapeutics N/A -52.89% -48.18% Neoleukin Therapeutics N/A -37.22% -30.91%

Do analysts recommend NLTX or AKTS?

Aktis Oncology has a consensus target price of $35.00, suggesting a potential upside of 31.33%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aktis Oncology 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90

Is NLTX or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Aktis Oncology N/A N/A N/A

Do analysts rate NLTX or ORIC?

Oric Pharmaceuticals has a consensus target price of $19.45, indicating a potential upside of 52.70%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oric Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.80

Which has better earnings and valuation, NLTX or ORIC?

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neoleukin Therapeutics N/A N/A -$57.56M -$3.11 N/A Oric Pharmaceuticals N/A N/A -$129.47M -$1.35 N/A

Is NLTX or ORIC more profitable?

Oric Pharmaceuticals' return on equity of -35.35% beat Neoleukin Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Oric Pharmaceuticals N/A -35.35% -33.39%

Neoleukin Therapeutics (NLTX) Competitors

$38.36 +0.49 (+1.29%)

As of 09/2/2026

Compare

NLTX vs. ALVO, REPL, CGEM, AKTS, and ORIC

Should you buy Neoleukin Therapeutics stock or one of its competitors? Neoleukin Therapeutics's main competitors and comparable companies include Alvotech (ALVO), Replimune Group (REPL), Cullinan Therapeutics (CGEM), Aktis Oncology (AKTS), and Oric Pharmaceuticals (ORIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Neoleukin Therapeutics compare to Alvotech?

Neoleukin Therapeutics (NASDAQ:NLTX) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.22, suggesting that its share price is 78% less volatile than the broader market.

In the previous week, Alvotech had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Alvotech and 0 mentions for Neoleukin Therapeutics. Alvotech's average media sentiment score of 0.45 beat Neoleukin Therapeutics' score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Alvotech	Neutral

Alvotech has a consensus price target of $7.50, indicating a potential upside of 39.41%. Given Alvotech's stronger consensus rating and higher possible upside, analysts plainly believe Alvotech is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alvotech	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.25

Alvotech has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Alvotech	$588.90M	2.76	$27.92M	-$0.61	N/A

Neoleukin Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -36.31%. Alvotech's return on equity of -11.92% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Alvotech	-36.31%	-11.92%	-11.73%

52.4% of Neoleukin Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 0.5% of Alvotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Alvotech beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Replimune Group?

Neoleukin Therapeutics (NASDAQ:NLTX) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk.

Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Replimune Group has a consensus price target of $12.00, indicating a potential downside of 21.52%. Given Replimune Group's stronger consensus rating and higher possible upside, analysts plainly believe Replimune Group is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by company insiders. Comparatively, 5.4% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Replimune Group had 24 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 24 mentions for Replimune Group and 0 mentions for Neoleukin Therapeutics. Replimune Group's average media sentiment score of 0.45 beat Neoleukin Therapeutics' score of 0.00 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Replimune Group	Neutral

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Neoleukin Therapeutics' return on equity of -37.22% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Replimune Group	N/A	-159.32%	-90.84%

Summary

Replimune Group beats Neoleukin Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Cullinan Therapeutics had 4 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 4 mentions for Cullinan Therapeutics and 0 mentions for Neoleukin Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.18 beat Neoleukin Therapeutics' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cullinan Therapeutics	Positive
Neoleukin Therapeutics	Neutral

Cullinan Therapeutics has a beta of 0.02, suggesting that its share price is 98% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Cullinan Therapeutics currently has a consensus price target of $32.86, indicating a potential upside of 48.27%. Given Cullinan Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Cullinan Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Neoleukin Therapeutics' return on equity of -37.22% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cullinan Therapeutics beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Aktis Oncology?

Neoleukin Therapeutics (NASDAQ:NLTX) and Aktis Oncology (NASDAQ:AKTS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

In the previous week, Aktis Oncology had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 5 mentions for Aktis Oncology and 0 mentions for Neoleukin Therapeutics. Aktis Oncology's average media sentiment score of 1.59 beat Neoleukin Therapeutics' score of 0.00 indicating that Aktis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Aktis Oncology	Very Positive

Aktis Oncology has a consensus target price of $35.00, suggesting a potential upside of 31.33%. Given Aktis Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Aktis Oncology is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Neoleukin Therapeutics has higher earnings, but lower revenue than Aktis Oncology. Aktis Oncology is trading at a lower price-to-earnings ratio than Neoleukin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Aktis Oncology	$6.50M	220.38	-$63.73M	-$0.82	N/A

Aktis Oncology's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Aktis Oncology	N/A	N/A	N/A

52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 3.3% of Aktis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Aktis Oncology beats Neoleukin Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Neoleukin Therapeutics compare to Oric Pharmaceuticals?

Neoleukin Therapeutics (NASDAQ:NLTX) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

In the previous week, Oric Pharmaceuticals had 7 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 7 mentions for Oric Pharmaceuticals and 0 mentions for Neoleukin Therapeutics. Oric Pharmaceuticals' average media sentiment score of 0.95 beat Neoleukin Therapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Oric Pharmaceuticals	Positive

Oric Pharmaceuticals' return on equity of -35.35% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Oric Pharmaceuticals	N/A	-35.35%	-33.39%

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.35	N/A

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Oric Pharmaceuticals has a consensus target price of $19.45, indicating a potential upside of 52.70%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oric Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Summary

Oric Pharmaceuticals beats Neoleukin Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Neoleukin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NLTX vs. The Competition

Export

Metric	Neoleukin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$360.51M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-12.33	12.66	273.28	25.38
Price / Sales	N/A	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	3.46	16.29	12.89	6.14
Net Income	-$57.56M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-0.13%	-1.37%	-0.33%	-1.47%
1 Month Performance	16.63%	11.07%	6.51%	2.47%
1 Year Performance	95.32%	53.71%	25.19%	15.84%

Neoleukin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NLTX Neoleukin Therapeutics	N/A	$38.36 +1.3%	N/A	+104.9%	$360.51M	N/A	N/A	90	High Trading Volume
ALVO Alvotech	2.8267 of 5 stars	$4.91 -2.8%	$7.50 +52.7%	-32.8%	$1.52B	$588.90M	N/A	1,460	Analyst Upgrade
REPL Replimune Group	2.066 of 5 stars	$15.88 +0.5%	$12.00 -24.4%	+170.8%	$1.48B	N/A	N/A	210
CGEM Cullinan Therapeutics	2.9235 of 5 stars	$22.85 -0.4%	$32.86 +43.8%	+198.1%	$1.48B	N/A	N/A	30	Positive News
AKTS Aktis Oncology	2.9862 of 5 stars	$26.51 -0.7%	$35.00 +32.0%	N/A	$1.43B	$6.50M	N/A	76

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NLTX) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. ALVO, REPL, CGEM, AKTS, and ORIC

How does Neoleukin Therapeutics compare to Alvotech?

Summary

How does Neoleukin Therapeutics compare to Replimune Group?

Summary

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Summary

How does Neoleukin Therapeutics compare to Oric Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neoleukin Therapeutics (NLTX) Competitors

NLTX vs. ALVO, REPL, CGEM, AKTS, and ORIC

How does Neoleukin Therapeutics compare to Alvotech?

Which has more volatility & risk, NLTX or ALVO?

Does the media refer more to NLTX or ALVO?

Do analysts recommend NLTX or ALVO?

Which has preferable earnings & valuation, NLTX or ALVO?

Is NLTX or ALVO more profitable?

Do insiders and institutionals have more ownership in NLTX or ALVO?

Summary

How does Neoleukin Therapeutics compare to Replimune Group?

Which has more volatility & risk, NLTX or REPL?

Do analysts prefer NLTX or REPL?

Do insiders & institutionals believe in NLTX or REPL?

Does the media refer more to NLTX or REPL?

Which has preferable valuation and earnings, NLTX or REPL?

Is NLTX or REPL more profitable?

Summary

How does Neoleukin Therapeutics compare to Cullinan Therapeutics?

Does the media prefer CGEM or NLTX?

Which has more risk & volatility, CGEM or NLTX?

Which has better valuation and earnings, CGEM or NLTX?

Do analysts recommend CGEM or NLTX?

Is CGEM or NLTX more profitable?

Do insiders and institutionals have more ownership in CGEM or NLTX?

Summary

How does Neoleukin Therapeutics compare to Aktis Oncology?

Does the media refer more to NLTX or AKTS?

Do analysts recommend NLTX or AKTS?

Which has stronger valuation & earnings, NLTX or AKTS?

Is NLTX or AKTS more profitable?

Do institutionals & insiders hold more shares of NLTX or AKTS?

Summary

How does Neoleukin Therapeutics compare to Oric Pharmaceuticals?

Does the media favor NLTX or ORIC?

Is NLTX or ORIC more profitable?

Which has better earnings and valuation, NLTX or ORIC?

Do institutionals and insiders believe in NLTX or ORIC?

Do analysts rate NLTX or ORIC?

Which has more volatility & risk, NLTX or ORIC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NLTX vs. The Competition

Neoleukin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools